Reply  by Buckley, Clifford J. et al.
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Volume 53, Number 2 Letters to the Editor 561imal superficial femoral artery) no ligation or only distal ligation
was performed. This opens the way for back bleeding from collat-
erals and growth of the aneurysm. Ongoing growth of the aneu-
rysm after open PAA repair has also been described in other
reports, with a similar incidence.3,4 Mehta et al4 reported 10 of 26
patients (38%) showing flow in the aneurysmal sac after a follow-up
of 38 months, with 23% demonstrating growth of the aneurysm
and 12% ruptures.4
The importance of both proximal and distal ligation as close to
the aneurysm as possible is therefore now generally recognized.
But even then, collaterals originating from the aneurysm itself can
be the source of continuous sac flow. No single report describes
similar effects after endovascular PAA repair. However, this is an
important question.
In this respect, we reviewed our data regarding endoleak and
aneurysm growth for the cohort of 78 PAAs with a mean follow-up
of 50 months.1 Of the 78 PAAs, 22 were followed-up in other
hospitals, and of the remaining 56 patients, 18 experienced stent
graft occlusion. Therefore, data on endoleak and growth for 38
PAAs were immediately available from our own hospital files up to
this date. In 21 patients (55.3%), the aneurysm proved to have
disappeared on duplex ultrasound imaging, and in 13 (34.2%), the
aneurysm had shrunk. In another two patients (5.3%), a type II
endoleak was seen on duplex, but the aneurysm did not grow.
Finally, two other aneurysms (5.3%) with an endoleak had grown
initially, from 32 to 42 mm and from 28 to 41 mm. They were
treated with ultrasound-guided percutaneous thrombin injection,
although they were asymptomatic, and have had a stable diameter
since then. This means that growth of the aneurysm only occurred
in 5% of the patients after endovascular repair. This figure is even
lower than the 8.3% (2 of 24) mentioned by Ravn et al2 with a
posterior approach in open surgery.
The explanation for the low incidence of type II endoleak and
aneurysm growth after endovascular PAA repair is probably that
the stent graft fills the lumen of the PAA and prevents back
bleeding in the landing zone due to apposition of the stent graft to
the wall of the vessel. It is clear that collaterals originating from the
aneurysm itself still can give rise to an endoleak, but apparently this
is rarely happening.
Ignace F. J. Tielliu, MD, PhD
Clark J. Zeebregts, MD, PhD
Eric L. G. Verhoeven, MD, PhD
Department of Surgery
Division of Vascular Surgery
University Medical Center Groningen
Groningen, The Netherlands
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tegarding “Inherent problems with randomized
linical trials with observational/no treatment arms”
The unusual conclusions in the article by Buckley et al1 that
ife-threatening diseases like abdominal aortic aneurysm (AAA)
should not be evaluated using RCTs containing an observa-
ion/no treatment arm” and that “intent-to-treat analysis . . .
hould not be used in this situation” were based on the authors’
elief that high crossover rates are an “inherent weakness” of these
tudies. This belief stems from a misunderstanding of the term
crossover.” A crossover occurs when a patient receives the alter-
ative intervention rather than the randomly assigned interven-
ion, and represents a serious protocol violation which, if suffi-
iently frequent, can obscure the trial results. The Aneurysm
etection and Management (ADAM) trial2 compared two strate-
ies in patients with an AAA 4.0 to 5.5 cm: immediate open repair
s surveillance with repair of AAA that enlarged to 5.5 cm or
reater. Patients in the surveillancegroupwhohad repairwhen theAAA
nlarged to 5.5 cm or greater were not crossovers, they were
reated according to protocol and, therefore, contribute to the
alid comparison of the outcomes of the two strategies. The
tatement by Buckley et al regarding the ADAM trial that “61.6%
f those randomized to ultrasound surveillance crossed over to
pen repair” is incorrect. As reported in the text and Figure 1 of the
DAM manuscript, less than 10% of the surveillance group had
epair off-protocol and represent crossovers.
Apart fromBuckley et al, there is near universal agreement that
andomized trials remain “the gold standard in evaluating health-
are interventions” and that intent-to-treat analysis remains an
ssential aspect of their validity.3 Randomized trials established the
enefit of coronary artery bypass surgery4 and carotid endarterec-
omy,5 and there is no “inherent” reason why AAA repair should
e studied any differently.
rank A. Lederle, MD
epartment of Medicine
eterans Affairs Medical Center
inneapolis, Minn
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The primary purpose of the authors’ article was to identify
otential problems, which can occur when large numbers of pa-
ients in randomized abdominal aortic aneurysm (AAA) clinical
rials cross over from no treatment to treatment.We feel these cross
vers obfuscate some of the trial’s conclusions. Despite comments
o the contrary, the predominant reasons for trial participants to
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February 2011562 Letters to the Editorcross over from no treatment to treatment was either aneurysm
becoming symptomatic, a very subjective event, or the patients’
request for treatment because of concerns related to their aneu-
rysm. Very few patients, in all of the trials cited, crossed over from
no treatment to treatment because of aneurysm size increases,
which exceeded the limits defined in the protocols. Subjective,
rather than objective, reasons for changing a randomized treat-
ment assignment can undermine, to some degree, the validity of
the trial.
While we appreciate the comments made to the editors reflect-
ing a need to defend the particular trial cited, we note that the
authors’ conclusions are even more sweeping than ours. We do not
claim that this problem is “universal” with, or that it negates the
conclusions of, all randomized trials of such design. We simply
reported that a crossover from no treatment to treatment was a
problem in the author’s experience with the PIVOTAL (Positive
Impact of Endovascular Options for Treating Aneurysms Early)
trial. In reviewing other trials of the same design, we found similar
problems in the examples cited, (ie, in which AAA intervention was
pitted against no treatment) the conclusions of such trials were
jeopardized, if not made controversial, by the significant crossover
rate. We are in no way generalizing or implying that randomized
trials are not the “gold standard” of level I evidence, as the Letter
to the Editor implies.
Clifford J. Buckley, MD
Shirley D. Buckley, MSN, RN
Texas A&M University College of Medicine
Division of Vascular Surgery
Temple, Tex
Robert B. Rutherford, MD
Professor Emeritus
University of Colorado College of Medicine
Denver, Colo
Edward B. Diethrich, MD
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Regarding “Endovenectomy of the common femoral
vein and intraoperative iliac vein recanalization for
chronic iliofemoral venous occlusion”
I recently had the privilege of reporting “Endovenectomy of
the common femoral vein and intraoperative iliac vein recanaliza-
tion for chronic iliofemoral venous occlusion”1 in a patient with
debilitating, chronic, postthrombotic occlusion of his iliofemoral
venous system. The article stated that this was the first report of
endovenectomy with endoluminal recanalization for patients such
as these.
Although this is a true statement regarding the peer-reviewed
literature, I saw this week that Dr Peter Gloviczki reported this
procedure in the fifth edition of Rutherford’s Vascular Surgery
textbook.2 I was not aware of his description in Vascular Surgery at
the time the article was written. Dr Gloviczki discussed this tech-
nique with me approximately 2 years ago, which stimulated the
team at the Jobst Vascular Center to pursue this treatment option
in patients with chronic, postthrombotic, iliofemoral venous
obstruction.
I want to recognize this important contribution of Dr
Gloviczki and his team at Mayo Clinic as being the catalyst for our
embarking on this technique and recognize that they were the first
to publish this concept. Thank you, Peter!
c
wnthony J. Comerota, MD
obst Vascular Center
oledo, Ohio
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egarding “Causes of late mortality after
ndovascular and open surgical repair of infrarenal
bdominal aortic aneurysms”
We read with great interest a large (13,971 patients) retro-
pective cohort study by Goodney et al1 of patients undergoing
ndovascular (EVAR) and open surgical repair (OSR) of abdomi-
al aortic aneurysm. As expected, early mortality occurred in
atients undergoing OSR, whereas deaths in patients undergoing
VAR occurred later. Although overall long-term mortality was
imilar in both cohorts (15.3% for EVAR and 15.9% for OSR at a
edian follow-up of 1.6 and 1.9 years, respectively), with an
djusted hazard ratio for mortality for patients undergoing EVAR
f 0.98 (95% confidence interval, 0.90-1.07), the two unadjusted
urvival curves crossed at approximately 1.6 years of follow-up. A
ossible explanation could be that patients undergoing EVAR have
ore comorbidity and thus may be more likely to die after dis-
harge than patients undergoing OSR.
To confirm whether crossing of survival curves occurs also in
andomized cohorts (equal-risk patients), we performed a meta-
nalysis of three well-known trials: Endovascular Aneurysm Repair
,2 Dutch Randomized Endovascular Aneurysm Management,3
nd Open Versus Endovascular Repair.4 The pooled cumulative
urvival rates were yielded by means of a strategy to combine
urvival data constructed by Pereira et al.5
In the first step, we redistributed in equal quantities at
-month intervals patients censored at intervals 1 month. Next,
e obtained the numbers of deaths for intervals of 1 month by
sing the patients at risk at the start of an interval, the redistributed
ensored patients, and the interval survival rates. We then calcu-
ated the Kaplan-Meier survival rates for each trial and each month
f follow-up and used these rates as treatment effects.
In the second step, we calculated a within-trials variance for
ach monthly survival rate in each trial; next, we calculated a
etween-trials variance for each month. To obtain pooled mea-
ures of treatment effect for each month of follow-up, we used in
he third step random-effects modeling.
Finally, the product of successive monthly pooled measures of
reatment effect allowed us to obtain pooled measures of cumula-
ive survival.
The pooled cumulative survival rates of EVAR and OSR were,
espectively, 97.8% and 94.4% at 1 month; 95.3% and 92.2% at 1
ear; 90.1% and 88.6% at 2 years; 82.8% and 83.4% at 3 years;
7.5% and 79.2% at 4 years; and 74.2% and 76.3% at 5 years
Fig). Two survival curves crossed at approximately 2.7 years of
ollow-up.
The results of our analysis suggest that crossing of survival
urves of EVAR and OSR occurs even in randomized cohorts
hough the intersection is delayed by approximately one year as
ompared with the retrospective cohorts in the study by Goodney
t al.1 To confirm whether the differences in mortality after the
rossing are increased, longer-term results of randomized trials
ould be needed.
